ライフサイエンスコーパス: idiopathic inflammatory myopathy

1 ; also known as Jo-1) in the pathogenesis of idiopathic inflammatory myopathy.

2 muscle inflammation that is the hallmark of idiopathic inflammatory myopathy.

3 d be undertaken in any patient with presumed idiopathic inflammatory myopathy.

4 ate immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies.

5 the optimal design of clinical trials in the idiopathic inflammatory myopathies.

6 the development of better therapies for the idiopathic inflammatory myopathies.

7 ggest that non-immunological factors promote idiopathic inflammatory myopathies.

8 mune responses and clinical syndromes in the idiopathic inflammatory myopathies.

9 ting the serial CMAS scores of children with idiopathic inflammatory myopathies.

10 sorders than the currently used designation, idiopathic inflammatory myopathies.

11 skeletal muscle involvement in patients with idiopathic inflammatory myopathies.

12 s of strength and endurance in children with idiopathic inflammatory myopathies.

13 assessing disease activity and damage in the idiopathic inflammatory myopathies and speculates on pos

14 The association between the idiopathic inflammatory myopathies and the development o

15 In this large series of patients with idiopathic inflammatory myopathy, anti-Jo-1 antibody lev

16 The idiopathic inflammatory myopathies are an important and

17 The idiopathic inflammatory myopathies are diseases that can

18 Inasmuch as the clinical features of the idiopathic inflammatory myopathies are not easily differ

19 eurin inhibitors are being used to treat the idiopathic inflammatory myopathies, but their efficacy h

20 teroviruses as potential etiologic agents of idiopathic inflammatory myopathy, but their relationship

21 Diseases that may mimic the idiopathic inflammatory myopathies can be differentiated

22 ing myopathy (IMNM) is considered one of the idiopathic inflammatory myopathies, comprising dermatomy

23 the pathogenesis and course of the juvenile idiopathic inflammatory myopathies continued this year.

24 dermatomyositis, polymyositis, and the other idiopathic inflammatory myopathies focus primarily on fe

25 nces in the development of therapies for the idiopathic inflammatory myopathies have been enabled by

26 New classification criteria for the idiopathic inflammatory myopathies have been proposed in

27 tions into possible infectious causes of the idiopathic inflammatory myopathies have focused on retro

28 our understanding of the pathogenesis of the idiopathic inflammatory myopathies have served to identi

29 The idiopathic inflammatory myopathies (IIM) continue to pro

30 the case for other autoimmune diseases, the idiopathic inflammatory myopathies (IIM) develop as a re

31 f patients with systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), and HLA-DQA1*0

32 ease damage, have not been developed for the idiopathic inflammatory myopathies (IIM), thus limiting

33 ry remain significant clinical challenges in idiopathic inflammatory myopathies (IIM).

34 rovement in clinical trials of patients with idiopathic inflammatory myopathy (IIM) has varied to dat

35 The sequelae associated with idiopathic inflammatory myopathy (IIM) often result in d

36 date the reader on immunogenetic advances in idiopathic inflammatory myopathy (IIM) over the past 18

37 ) and North American Caucasian patients with idiopathic inflammatory myopathy (IIM).

38 with myositis but without silicone implants (idiopathic inflammatory myopathy; IIM patients).

39 Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoim

40 Mechanisms driving the autoimmune process in idiopathic inflammatory myopathies (IIMs) have not been

41 en made in understanding the genetics of the idiopathic inflammatory myopathies (IIMs) in the past 2

42 Increasing evidence suggests that the idiopathic inflammatory myopathies (IIMs) result from ce

43 This update on childhood idiopathic inflammatory myopathies (IIMs) reviews recent

44 y contribute to the etiology of the juvenile idiopathic inflammatory myopathies (IIMs), which are sys

45 ns of birth dates in groups of patients with idiopathic inflammatory myopathies (IIMs).

46 le dermatomyositis is the most common of the idiopathic inflammatory myopathies in children.

47 most striking humoral characteristics of the idiopathic inflammatory myopathies is the specific targe

48 to advance our understanding of the juvenile idiopathic inflammatory myopathies (JIIMs).

49 py has shown the ability to diagnose several idiopathic inflammatory myopathy mimics.

50 The idiopathic inflammatory myopathies or myositis syndromes

51 Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndrome

52 Advances in dermatomyositis and the juvenile idiopathic inflammatory myopathies over the past year in

53 ome to the forefront in evaluating difficult idiopathic inflammatory myopathy patients.

54 In patients with juvenile idiopathic inflammatory myopathy, stair-stepping exercis

55 es should be distinguished from the commoner idiopathic inflammatory myopathies such as polymyositis

56 ve assessments of therapeutic strategies for idiopathic inflammatory myopathies were recently publish

57 were performed in 19 patients with juvenile idiopathic inflammatory myopathy who performed stair-ste

58 Methods for assessing target organs of the idiopathic inflammatory myopathies will likely evolve as

59 Dermatomyositis is one of the idiopathic inflammatory myopathies with characteristic c